Volume 6, Number 2—April 2000
Research
Serologic Response to Culture Filtrate Antigens of Mycobacterium ulcerans during Buruli Ulcer Disease
Karen M. Dobos*†, Ellen A. Spotts*†, Barbara J. Marston*, C. Robert Horsburgh*, and C. Harold King*
Table 2
Serologic and skin test responses of Buruli ulcer patients and healthy controls from the same villages
| Clinical presentation | Total Burulin (+)a | AB to MUCFb (+)c |
|---|---|---|
| Total BU patients (n = 39) | 28 (71.8) | 26 (66.7) |
| (%) | ||
| Healed (n = 16) | 15 (93.8) | 11 (68.8) |
| (%) | ||
| Ulcerative (n = 17) | 11 (64.7) | 11 (64.7) |
| (%) | ||
| Early ulcerative (n = 6) | 2 (33.4) | 4 (66.7) |
| (%) | ||
| No scar or ulcer (n = 21) | 3 (14.3) | 7 (33.3) |
| (%) |
aTotal Burulin (+) numbers and (%) are derived from columns one and two of Table 1 added together without regard to PPD status, and thus represent the highest possible number (percentage) of Burulin (+) BU patients.
bMUCF = Mycobacterium ulcerans culture filtrate.
cDenotes all BU patients and controls with any antibodies detected by Western blot analysis against MUCF.
Page created: December 16, 2010
Page updated: December 16, 2010
Page reviewed: December 16, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.